• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Growth hormone and IGF research: Official journal of the Growth Hormone Research Society and the International IGF Research Society >The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
【24h】

The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.

机译：在接受持续性pegvisomant治疗的肢端肥大症患者中，在6小时的试验中，急性单独应用pegvisomant或与奥曲肽联合应用对内源性GH水平的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: Co-treatment with somatostatin analogues and growth hormone receptor antagonists in acromegaly might be a new treatment option abolishing the negative effects of monotherapy. Nevertheless, little is known about the acute effect of the combined treatment on endogenous GH and pegvisomant levels. DESIGN: Ten acromegalic patients on constant pegvisomant therapy were included. Two 6-h GH secretion profiles were performed once after pegvisomant alone (P), the other after an additional 100 microg octreotide sc injection (PO). After 180 min, all patients received a standardized light mixed meal. Endogenous serum GH and pegvisomant levels were measured by special in-house assays. In addition, insulin and glucose were measured. RESULTS: In the combined profile PO, a significant decrease of median endogenous GH was seen (p<0.01, median percentage decline 75.2%, range 23.7-88.2), which was not seen in profile P. Seven of 10 patients had a decline >70% and might be seen as responders. After meal, endogenous GH significantly decreased only in profile P (p<0.01). Pegvisomant levels did not differ significantly between profiles and did not change significantly during the tests. After meal, glucose levels rose higher and later and insulin levels lower and later in profile PO than in profile P. CONCLUSION: During pegvisomant treatment, endogenous GH can be reduced significantly by acute application of a somatostatin analogue. Therefore, in acromegalic patients on pegvisomant therapy GH regulation due to somatostatin analogues seems to be preserved.
机译：目的：在肢端肥大症中与生长抑素类似物和生长激素受体拮抗剂共同治疗可能是消除单一疗法负面影响的新治疗选择。然而，关于联合治疗对内源性GH和培维索姆水平的急性作用知之甚少。设计：包括十名接受持续性培维索孟治疗的肢端肥大症患者。单独使用培维索孟（P）后，进行了两次6h GH分泌曲线分析，另外100 mg微克奥曲肽皮下注射（PO）后进行了另外6h GH分泌曲线分析。 180分钟后，所有患者均接受标准化的便餐。内源性血清GH和pegvisomant水平通过特殊的内部测定法进行测量。另外，测量了胰岛素和葡萄糖。结果：在组合型PO中，内源性GH的中位数显着下降（p <0.01，中位百分率下降75.2％，范围23.7-88.2），在P型中未见。10例患者中有七例下降> 70％，可能被视为响应者。进餐后，内源性GH仅在轮廓P中显着下降（p <0.01）。在配置文件之间，pegvisomant水平没有显着差异，并且在测试过程中也没有显着变化。进餐后，PO曲线中的葡萄糖水平比P曲线中的葡萄糖水平更高和更高，而胰岛素水平则更低和更高。结论：在培维索孟治疗期间，急性使用生长抑素类似物可以显着降低内源性GH。因此，在接受肢端肥大症治疗的肢端肥大症患者中，由于生长抑素类似物引起的GH调节似乎得以保留。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号